LEXX Chart by TradingView

Business Description

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide.

Website https://www.lexariabioscience.com/

FRC Analyst's Reports

Lexaria Bioscience Corp. (NASDAQ: LEXX) Drug Delivery Tech With Multiple Mainstream Applications – Resuming Coverage Aug. 16, 2021
Lexaria Bioscience (CSE: LXX) Focus Seemingly on R&D as Licensing Revenues Slow May. 7, 2019
Lexaria Bioscience (CSE: LXX) Landmark Partnership with Tobacco Titan Feb. 5, 2019
Lexaria (CSE: LXX) Additional Licensees and Expanded IP Aug. 31, 2018
Lexaria (OTCQX: LXRP / CSE: LXX) Initial Cannabis Focus; Multi-Market Potential Jan. 12, 2018

This company was mentioned in the following "Analysts’ Ideas Of The Week":

Investors are also interested in these companies: